ROIV PEER ANALYSIS

Roivant Sciences Ltd — metric-by-metric comparison with peers and the industry median

ROIVRoivant Sciences Ltd

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

ROIVIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	ROIV	CSL	TLX	MSB	Ind. Median
P/E	—	29.44	—	—	17.91
P/B	6.30	2.20●	6.37	—	3.51
EV/EBITDA	—	10.21●	120.14	—	14.82
P/S	3,454.68	2.62●	3.24	31.61	10.89

Financial Health
Metric	ROIV	CSL	TLX	MSB	Ind. Median
Current Ratio	18.37●	2.57	1.43	—	5.90
Debt/Equity	2.4%●	67.4%	112.3%	—	10.9%
NetDebt/EBITDA	16.03	2.22●	13.13	—	1.15

Profitability
Metric	ROIV	CSL	TLX	MSB	Ind. Median
Net Margin	-3,629.2%	9.2%●	-0.9%	-115.3%	-125.7%
ROE	-6.5%	7.7%●	-1.8%	-11.3%	-47.5%
ROA	-5.4%	3.8%●	-0.7%	-8.6%	-35.8%
EBITDA Margin	-3,162.6%	32.8%●	3.0%	-76.6%	-105.8%

Growth + Dividend
Metric	ROIV	CSL	TLX	MSB	Ind. Median
Rev. Growth	-67.7%	4.8%	56.3%	410.4%●	5.1%
NI Growth	—	-39.4%	—	—	12.1%
Div. Yield	—	2.5%●	—	0.0%	0.2%
Payout	—	103.1%	—	0.0%	0.0%

Valuation
Metric	ROIV	MRNA	RPRX	INCY	INSM	RVMD	Ind. Median
P/E	—	—	39.06	16.88●	—	—	17.91
P/B	6.30	4.25●	4.69	4.35	34.12	24.99	3.51
EV/EBITDA	—	—	23.94	10.79●	—	—	14.82
P/S	3,454.68	14.16	13.25	4.51●	29.34	—	10.89

Financial Health
Metric	ROIV	MRNA	RPRX	INCY	INSM	RVMD	Ind. Median
Current Ratio	18.37●	2.41	2.66	3.68	4.47	6.80	5.90
Debt/Equity	2.4%	17.5%	130.0%	0.6%●	106.2%	29.2%	10.9%
NetDebt/EBITDA	16.03	1.35	4.91	-2.13●	0.44	1.12	1.15

Profitability
Metric	ROIV	MRNA	RPRX	INCY	INSM	RVMD	Ind. Median
Net Margin	-3,629.2%	-143.6%	33.9%●	26.7%	-144.4%	—	-125.7%
ROE	-6.5%	-36.6%	12.2%	31.1%●	-294.5%	-76.7%	-47.5%
ROA	-5.4%	-26.4%	4.4%	21.9%●	-61.0%	-59.4%	-35.8%
EBITDA Margin	-3,162.6%	-129.7%	69.6%●	34.9%	-131.9%	—	-105.8%

Growth + Dividend
Metric	ROIV	MRNA	RPRX	INCY	INSM	RVMD	Ind. Median
Rev. Growth	-67.7%	-29.1%	7.8%	21.5%	115.1%●	-100.0%	5.1%
NI Growth	—	—	-24.3%	6,631.4%●	—	—	12.1%
Div. Yield	—	—	1.6%	—	—	—	0.2%
Payout	—	—	46.8%	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on ROIV

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.